UNSPSC 51142421: Naratriptan

This classification denotes a serotonin agonist with the molecular formula C17H25N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QX3KXL1ZA2, chemically known as 1h-indole-5-ethanesulfonamide, n-methyl-3-(1-methyl-4-piperidinyl)- but generally known as naratriptan, which bears US NIH Compound Identifier 4440. European Medicines Agency schedules Naratriptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09164MIG.

UNSPSC 51142421 Naratriptan is a Commodity code representing pharmaceutical products, but the recent state and local solicitations tagged under it reflect a much broader pharmaceutical procurement landscape — generic multi-source drugs, over-the-counter products, naloxone and drug deactivation systems, and direct-to-manufacturer prescription program administration rather than naratriptan specifically. State and local governments under this code are buying pharmaceutical supply agreements through cooperative purchasing vehicles, direct county health procurement, and state health commission pharmacy benefit initiatives. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across participating jurisdictions including Oregon and Minnesota).

Recent activity spans Florida, Texas, Minnesota, and Oregon. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring manufacturers to supply through authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certification; the contract term is two years with optional extensions, and evaluation will weight price competitiveness at 75 percent. Seminole County, Florida posted an IFB on June 30, 2026 for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries, due July 26, 2023, requiring electronic bid submission and E-Verify compliance. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM and GPO channels, representing exploratory market research rather than a competitive award.